Spondyloarthritis & psoriatic arthritis
Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study
Authors' conclusion
Multimodal imaging with HR-pQCT and MRI showed no relevant progression of structural bone damage over 48 months in patients with PsA treated with secukinumab
Study context
- Population
- Adult patients with active psoriatic arthritis (PsA)40.6% female, mean age 56±7.5 years
- Participants
- 32 patients
- Outcome
- Structural bone changes on HR-pQCT and MRI
- Follow-up
- 48 months
Methodological detailssingle-arm, longitudinal high-resolution peripheral quantitative CT (HR-pQCT) and MRI imaging
- Single-arm
- Longitudinal HR-pQCT and MRI imaging
Main finding
As reported in the abstract
48 months
MRI Psoriatic Arthritis MRI Score (PsAMRIS) erosion subitem, increase
+1.4
MRI PsAMRIS osteoproliferation subitem, increase
+0.8
Observational data: associations, not effects.
Further findings
Drug survival · 48 months
- Drug survival rate
- 68.8%
Clinical outcomes, change from baseline
- DAS28, significant improvement
- P < 0.001
- Leeds Enthesitis Index, significant improvement
- P = 0.027
- PASI, significant improvement
- P = 0.001
- CRP
- P = 0.09
- Psoriatic Arthritis Impact of Disease, significant improvement
- P < 0.001
- Pain, significant improvement
- P < 0.001
- Functional status (HAQ) remained stable
MRI PsAMRIS subitems, change
- Erosion subitem increased marginally
- +1.4
- Osteoproliferation subitem increased marginally
- +0.8
- Inflammatory changes remained stably low
Original publication
Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study. RMD Open. Published 25 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →